Exosomal biomarkers in the differential diagnosis of ovarian tumors: the emerging roles of CA125, HE4, and C5a

Table 7 Prognostic unifactorial analysis of 34 patients with ovarian malignancy

	Considerations	N(%)	Χ2	P		Considerations	N(%)	Χ2	P
Age(y)	>50	14(64.3%)	0.657	0.417	E-C5a(ng/ml)	>7.4	17(64.7%)	1.285	0.257
Age(y)	≤ 50	20(75.0%)			E-C5a(ng/ml)	≤ 7.4	17(76.5%)
menopausal	Premenopausal	13(69.2%)	0.076	0.782	OCS	>0.600	22(83.3%)	3.509	0.061
menopausal	Postmenopausal	21(71.4%)			OCS	≤ 0.600	12(63.6%)
grade	I ~ II	18(88.9%)	5.012	0.025	S-CA125(U/ml)	>300	14(64.3%)	0.342	0.559
grade	III ~ IV	16(50.0%)			S-CA125(U/ml)	≤ 300	20(75.0%)
physiology	Epithelial	29(69.0%)	0.396	0.529	S-HE4(pmol/L)	a	20(60.0%)	4.007	0.045
physiology	others	5(80.0%)			S-HE4(pmol/L)	b	14(85.7%)
E-CA125(U/ml)	>125	13(84.6%)	1.613	0.204	ROMA(%)	c	18(66.7%)	0.624	0.430
E-CA125(U/ml)	≤ 125	21(61.9%)			ROMA(%)	d	16(75.0%)
E-HE4(pmol/L)	>3.5	15(73.3%)	0.106	0.744
E-HE4(pmol/L)	≤ 3.5	19(68.4%)

- a: Serum HE4 levels greater than 100 pmol/L in premenopausal women or greater than 170 pmol/L in postmenopausal women
- b: Serum HE4 levels less than or equal to 100 pmol/L in premenopausal women or less than or equal to 170 pmol/L in postmenopausal women
- c: ROMA index greater than 20 in premenopausal women or greater than 40 in postmenopausal women
- d: ROMA index less than or equal to 20 in premenopausal women or less than or equal to 40 in postmenopausal women

ISSN: 1757-2215